Translational Research in Child and Adolescent Cancer : VHIR Annual Report 2020

Oncology

< Back

Overview

In 2020, the Area has been composed by eight groups addressing main unsolved issues in cancer, covering the fields of child and adolescent cancer, melanoma, gynecology, urology, cancer stem cells and molecular mechanisms of the tumor pathologies, as well nanomedicine. We work in close collaboration with the corresponding departments at the Hospital. This provides a unique opportunity to tackle the abovementioned pathologies during the entire course of the disease, from diagnosis (a focus and strength of our Area) to personalized treatment (gathering important international impact during 2020 in the field of child cancer). Our research in 2020 has been relevant also in the field of the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics. Despite, the COVID-19 pandemic, the Area has kept active at virtual shared activities and ONCO-VHIR seminars and the organization of the World Cancer Day event to get closer to the society. During 2020 in-Campus collaborations with VHIO have been strengthen and internalization of our research has been amplified. It is also noteworthy the shared scientific production in terms of publications between different groups of the Area and the stable collaborations between groups that have consolidated during these period.

Publications

174
total
926
impact factor
5.32
average impact factor

Group Leader: Soledad Gallego Melcón

group-team team group-zoom zoom group-download download

Research Areas

In 2020, the group of Translational Research in Child and Adolescent Cancer maintained its research lines, namely on Soft Tissue Sarcomas (e.g. Rhabdomyosarcoma), Neural tumours (e.g. Neuroblastoma, Ependymoma) and the program of personalized medicine. In addition, the group also incorporated a new research line on Rare Anemia Disorders (e.g. Sickle cell disease). This research yielded the publication of 61 new international papers with an accumulated impact factor (JCR 2019) of 385. The group has continued with the consolidated collaborations with biotech companies to test and develop new therapies against the most aggressive pediatric solid tumors, with 3 patents ongoing, one of them entering national phases in 2020. Moreover, we have also a line of research to take profit of liquid biopsy to develop a system based on NGS to monitorize the probability of relapses.

Furthermore, the group is currently running 57 clinical trials with the most advanced treatments for childhood tumors.

VHIR Annual Report 2020

© FIR-HUVH Fundació Institut de Recerca Hospital Universitari Vall d’Hebron 2019 | Developed by: ondeuev